

**CLAIMS**

1. The use of an inhibitor of IL-17 activity for the manufacture of a medicament for the treatment and/or prophylaxis of multiple sclerosis (MS).
- 5 2. The use according to claim 1, wherein the inhibitor is a small molecule (NCE).
3. The use according to claim 1, wherein the inhibitor is a nucleic acid.
4. The use according to claim 1, wherein the inhibitor is an antibody or functionally active fragment or derivative thereof.
5. The use according to claim 4, wherein the antibody or fragment thereof is  
10 monoclonal, polyclonal, chimeric, humanised or bispecific.
6. The use according to claim 4 or claim 5 where the antibody fragment is a Fab, Fab', F(ab')<sub>2</sub>, scFv or an epitope-binding fragment thereof.
7. The use according to any one of claims 4-6 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
- 15 8. The use according to any one of claims 4-7 in which the antibody or fragment thereof binds to IL-17.
9. The use according to any one of claims 4-7 in which the antibody or fragment thereof binds to IL-17R.
10. A method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising  
20 administering a therapeutically effective amount of an inhibitor of IL-17 activity.
11. The method according to claim 10, wherein the inhibitor is a small molecule (NCE).
12. The method according to claim 10, wherein the inhibitor is a nucleic acid.
13. The method according to claim 10, wherein the inhibitor is an antibody or a functionally active fragment or derivative thereof.
- 25 14. The method according to claim 13, wherein the antibody or fragment thereof is monoclonal, polyclonal, chimeric, humanised or bispecific.
15. The method according to claim 13 or claim 14 where the antibody fragment is a Fab, Fab', F(ab')<sub>2</sub>, scFv or epitope binding fragment thereof.
16. The method according to any one of claims 13-15 wherein the antibody or fragment  
30 thereof is conjugated to one or more effector molecule(s).
17. The method according to any one of claims 13-16 in which the antibody or fragment thereof binds to IL-17.

18. The method according to any one of claims 13-16 in which the antibody or fragment thereof binds to IL-17R.
19. The method according to any one of claims 10-18 where the inhibitor of IL-17 activity is administered in combination with one or more other therapeutically active compounds.